Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lymphoma 43Breast Neoplasms 37Lymphoma, Large B-Cell, Diffuse 29Sarcoma 20Lymphoma, Non-Hodgkin 17Burkitt Lymphoma 16Neuroblastoma 15Leukemia 13HIV Infections 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Hodgkin Disease 11Acquired Immunodeficiency Syndrome 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Ovarian Neoplasms 9Multiple Myeloma 9Carcinoma, Hepatocellular 9Lymphoma, Large-Cell, Immunoblastic 8Lymphoma, Follicular 8Liver Neoplasms 8Liposarcoma 7Breast Neoplasms, Male 7Lymphoma, Mantle-Cell 6Lymphoma, Large-Cell, Anaplastic 6Fallopian Tube Neoplasms 6Sarcoma, Kaposi 5Neoplasms, Plasma Cell 5Lymphoma, B-Cell 5Lung Neoplasms 5Histiocytoma, Malignant Fibrous 5Fibrosarcoma 5

Interventions

temsirolimus 1dehydroftorafur 1Vincristine 1Sirolimus 1Razoxane 1Platinum 1Liver Transplantation 1Irinotecan 1Fluorouracil 1Doxorubicin 1Dexrazoxane 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × PRETEXT I Hepatoblastoma × Doxorubicin × Clear all
NCT00980460 2026-05-04

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
236 enrolled 18 charts
Gastrointestinal

PRETEXT I Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡